Koumprentziotis Ioannis-Alexios, Kroumpouzos Eleni, Delavar Shohreh, Kroumpouzos George
First Department of Dermatology and Venereology, Medical School, "Andreas Sygros" Hospital for Skin Diseases, National and Kapodistrian University of Athens, Athens, Greece.
LifeNet Health, Virginia Beach, Virginia, USA.
Clin Dermatol. 2025 Jul 29. doi: 10.1016/j.clindermatol.2025.07.006.
Microneedling radiofrequency (MNRF) and exosome therapies have recently garnered attention as potential treatments for pattern hair loss (PHL). This study aimed to conduct a scoping review of these treatments and present a series of patients with PHL treated with MNRF followed by topical exosome application therapy. We searched the PubMed, Google Scholar, and Cochrane databases for relevant articles regarding MNRF and exosome treatments for PHL. Our search yielded two studies on MNRF and nine studies on exosome therapy, all of which demonstrated positive effects on hair regrowth. One of these studies specifically focused on MN combined with exosome therapy. In our current study, we prospectively evaluated the efficacy and safety of MNRF followed by topical exosome application in 20 patients (median age, 46 years), comprising 16 men and four women, with PHL. Clinical evaluations were conducted using macroscopic photographs and digital image analysis with a trichoscopy device at baseline and then again at three, six, and nine months after treatment. The median followup duration was 10 months. Our results revealed significant increases in mean hair density and diameter, along with high patient satisfaction. No adverse events were reported. The treatment response was found to be independent of sex and the severity of PHL. Overall, this study underscores the potential therapeutic benefits of the MNRF followed by topical exosome application therapy. Randomized controlled trials, however, are needed to confirm the efficacy of this therapy and to determine the optimal treatment parameters. Pattern hair loss (PHL), also known as androgenetic alopecia, is a multifactorial condition influenced by genetic factors, mineral deficiencies, hormonal imbalances, and psychologic stress. Currently, topical minoxidil and oral finasteride are the only approved PHL treatments by the US Food and Drug Administration, with reported efficacy between 40% and 60%. Their use, however, is limited due to potential side effects such as dermatitis, headaches, sexual dysfunction, and muscle atrophy. To overcome such limitations and optimize efficacy, alternative therapies have been developed, including low-level laser therapy, microneedling (MN), platelet-rich plasma, and stem cell-based treatments. Identifying a treatment with high efficacy and minimal adverse effects, nevertheless, remains challenging. Among newer modalities, MN radiofrequency (RF; MNRF) and exosome therapies have gained increasing attention. Exosomes are cell-free, containing signaling proteins and growth factors that promote hair follicle regeneration by activating the Wnt-β-catenin pathway, prolonging the anagen phase, and preventing follicular miniaturization. MNRF delivers bipolar RF through microneedles, creating controlled thermal injury to stimulate hair regrowth. Combining MNRF with exosomes (MNRF-Exo) enhances targeted delivery to hair follicles, which may boost their therapeutic effects.
微针射频(MNRF)和外泌体疗法最近作为治疗雄激素性脱发(PHL)的潜在方法而受到关注。本研究旨在对这些治疗方法进行范围综述,并介绍一系列接受MNRF治疗后再进行局部外泌体应用治疗的PHL患者。我们在PubMed、谷歌学术和Cochrane数据库中搜索了有关MNRF和外泌体治疗PHL的相关文章。我们的搜索产生了两项关于MNRF的研究和九项关于外泌体疗法的研究,所有这些研究都表明对毛发生长有积极作用。其中一项研究专门关注MN与外泌体疗法的联合应用。在我们目前的研究中,我们前瞻性地评估了MNRF后再进行局部外泌体应用对20例(中位年龄46岁)PHL患者(包括16名男性和4名女性)的疗效和安全性。在基线时以及治疗后3个月、6个月和9个月使用宏观照片和带有毛发镜设备的数字图像分析进行临床评估。中位随访时间为10个月。我们的结果显示平均头发密度和直径显著增加,患者满意度也很高。未报告不良事件。发现治疗反应与性别和PHL的严重程度无关。总体而言,本研究强调了MNRF后再进行局部外泌体应用疗法的潜在治疗益处。然而,需要进行随机对照试验来证实这种疗法的疗效并确定最佳治疗参数。雄激素性脱发(PHL),也称为雄激素性秃发,是一种受遗传因素、矿物质缺乏、激素失衡和心理压力影响的多因素疾病。目前,局部米诺地尔和口服非那雄胺是美国食品药品监督管理局唯一批准的PHL治疗方法,报道的疗效在40%至60%之间。然而,由于潜在的副作用,如皮炎、头痛、性功能障碍和肌肉萎缩,它们的使用受到限制。为了克服这些限制并优化疗效,已经开发了替代疗法,包括低能量激光疗法、微针(MN)、富血小板血浆和基于干细胞的治疗方法。然而,找到一种疗效高且副作用最小的治疗方法仍然具有挑战性。在较新的治疗方式中,MN射频(RF;MNRF)和外泌体疗法越来越受到关注。外泌体是无细胞的,含有信号蛋白和生长因子,通过激活Wnt-β-连环蛋白途径、延长生长期和防止毛囊微型化来促进毛囊再生。MNRF通过微针传递双极射频,造成可控的热损伤以刺激毛发生长。将MNRF与外泌体联合使用(MNRF-Exo)可增强对外毛根鞘的靶向递送,这可能会提高它们的治疗效果。